中西医结合诊治慢性阻塞性肺疾病中国中医科学院-培训课件.ppt

* ? GlaxoSmithKline * ? GlaxoSmithKline 2002 * Adapted from Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD.Chest 1999; 115: 957-65. * ? GlaxoSmithKline 2002 * ODonnell DE, Webb KA. Mechanisms of improved exercise performance in response to salmeterol therapy in COPD.Am J Respir Crit Care Med 2002; 165(8): A506 * ? GlaxoSmithKline 2002 * Adapted from Burge PS, Calverley PMA, Jones PW, et al. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303. * Spencer S, Calverley PMA, Burge S, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med 2001; 163: 122-128. Official Journal of the American Thoracic Society ? American Thoracic Society * * Global initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart Lung and Blood Institute, April 2001; update of the Management sections, GOLD website (). Date updated: July 2003 * ? GlaxoSmithKline 2002 * * * * Global initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart Lung and Blood Institute, April 2001; update of the Management sections, GOLD website (). Date updated: July 2003 This slide summarises the recommendations for treatment at each stage of the GOLD guidelines Tristan研究 入选标准 符合欧洲COPD诊断标准 过去3年中出现过恶化 低可逆性 ( 10% FEV1预计值) 用药前FEV1 25-70% 预计值 FEV1/FVC 70% 排除标准 目前诊断为哮喘、湿疹、过敏性鼻炎的病人 过去4周使用过全身激素、抗菌素或改变原先COPD用药的病人 0 13 39 52 26 -2 Week Placebo run-in 双盲治疗期 Seretide 50/500μg bid Fluticasone 500μg bid Salmeterol 50μg bid Placebo Placebo Tristan, data On File Tristan